Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Ide Smets MD, PhD

Ide Smets MD, PhD

Consultant Neurologist, MS Center ErasMS, Department of Neurology, Erasmus MC, Rotterdam, The Netherlands

Ide Smets obtained her PhD in 2018 at the Catholic University of Leuven, and uncovered how one of the genetic variants in MS exerts his risk-increase effect on the immune system. In 2019, she graduated subsequently as a neurologist at University Hospitals Leuven. Being awarded with an ECTRIMS clinical fellowship award, she continued her training as an MS specialist at Barts-MS in London under supervision of prof. Giovannoni.

From 2022 onwards she works as a consultant neurologist in MS centre ErasMS which is part of the department of Neurology at the Erasmus University Medical Center Rotterdam. She cares about informed treatment choices by designing an online disease-modifying treatment (DMT) comparison tool at the www.clinicspeak.com website. Furthermore, she focuses on targeted and cost-effective application of DMTs in MS. Besides her research, she is a member of the MS working group of the Dutch Society for Neurology and the European and American Academy for Neurology.

Disclosures

Ide Smets has received lecture and/or consultancy fee from Merck, Biogen Idec and Sanofi Genzyme.